Caribou Biosciences (CRBU) Cash from Operations Growth (1y) (2021 - 2026)
Caribou Biosciences (CRBU) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 158.60% |
| 10 | Caribou Biosciences | 154.82 Mn | 37.19 Mn | - | 26.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.52% |
| Dec 31, 2025 | 41.38% |
| Sep 30, 2025 | 22.79% |
| Jun 30, 2025 | 14.02% |
| Mar 31, 2025 | 1.28% |
| Dec 31, 2024 | -65.91% |
| Sep 30, 2024 | -13.45% |
| Jun 30, 2024 | -116.44% |
| Mar 31, 2024 | -33.16% |
| Dec 31, 2023 | 14.63% |
| Sep 30, 2023 | -28.66% |
| Jun 30, 2023 | 30.58% |
| Mar 31, 2023 | -28.91% |
| Dec 31, 2022 | -17.09% |
| Sep 30, 2022 | -49.50% |
| Jun 30, 2022 | -32.76% |
| Mar 31, 2022 | -206.70% |
| Dec 31, 2021 | -164.85% |
| Sep 30, 2021 | -72.21% |